Ozempic / Wegovy (GLP-1) Leads
Reach patients who suffered severe gastrointestinal injuries and other serious side effects from semaglutide-based GLP-1 receptor agonist medications.
Ozempic / Wegovy GLP-1 Litigation
Ozempic and Wegovy, both semaglutide-based GLP-1 receptor agonists manufactured by Novo Nordisk, have been linked to severe gastrointestinal side effects that were not adequately disclosed on product labeling. Patients prescribed these medications for diabetes or weight loss have reported gastroparesis, bowel obstruction, and pancreatitis, among other serious conditions. Lawsuits allege the manufacturer failed to warn about the full scope and severity of these risks.
Associated Conditions
- Gastroparesis (stomach paralysis)
- Bowel obstruction
- Pancreatitis
- Gallbladder disease
- Intestinal blockage
- Severe nausea and vomiting requiring hospitalization
- Ileus (intestinal dysfunction)
Claimant Eligibility
- Prescribed Ozempic, Wegovy, or other semaglutide-based medication
- Experienced severe gastrointestinal side effects during or after use
- Required hospitalization or emergency treatment due to side effects
- Diagnosed with gastroparesis, bowel obstruction, or pancreatitis
- Side effects occurred while using or shortly after discontinuing the medication
Why Law Firms Choose Us
Exclusive Leads
Every lead is yours alone. We never resell or share claimant information with competing firms, guaranteeing you first-mover advantage on every case.
Pre-Qualified Claimants
Our intake specialists screen every potential claimant against your specific case criteria before delivery, so your team only speaks with viable cases.
Live Transfer
Qualified claimants are transferred directly to your intake team in real time, maximizing conversion rates and reducing time-to-retainer.
Ready to Scale Your Mass Tort Practice?
Tell us about your firm and a mass tort strategist will reach out within one business day.
Trusted by 200+ law firms nationwide